Skip to main content
About Us
Image Credits
Contributor Info
RSS
Log In
Join
Twitter
E-Alerts
Visit StemJournal
Main menu
About
Image Credits
Contributor Info
E-Alerts
Chapters
Cellular and nuclear reprogramming
Ectoderm specification and differentiation
Endoderm specification and differentiation
Epigenetics
Genomics and proteomics
Germ cell and somatic stem cell biology in reproduction
Manufacturing
Mesoderm specification and differentiation
Niche biology, homing, and migration
Renewal
Stem cell immunology
Therapeutic prospects
Tissue engineering
Protocols
Ectoderm differentiation
Endoderm differentiation
Genome editing
Mesoderm differentiation
Pluripotent stem cells
PSC characterization
PSC genetic stability
Reprogramming
StemLabs
Stem Cell COREdinates
Core Facility Profiles
Boston Children's Hospital Human Neuron Core
Boston University Center for Regenerative Medicine iPSC Core
Columbia Stem Cell Initiative Stem Cell Core Facility
Harvard Stem Cell Institute iPS Core Facility
Stem Cell Protocols
Stem Cell Reagents
Other Resources
News & Profiles
Latest News
Stem Cell Institute Profiles
Journal Stream
Forum
Search form
Search
You are here
Home
Biblio
Author
Title
Type
[
Year
]
Filters:
Author
is
Qin, Yazhen
[Clear All Filters]
2024
Hu L
,
Li Z
,
Yang S
,
Zhao T
,
Duan W
,
Qin Y
,
Jia J
,
Wang J
,
Lu S
,
Jiang H
, et al.
Allogeneic stem cell transplantation is still a highly curative therapy in adults with philadelphia chromosome-positive acute lymphoblastic leukaemia.
Ann Hematol. 2024.
PubMed
Google Scholar
2023
Li Y
,
Wang Y
,
Wang Z
,
Feng L
,
Gao L
,
Shi Y
,
Dang H
,
He Q
,
Qin Y
,
Jiang Q
, et al.
[Analysis of the characteristics of primary acute myeloid leukemia with 11q23/KMT2A rearrangements in ninety patients].
Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2023;40(12):1472-1477.
PubMed
Google Scholar
Jiang Q
,
Li Z
,
Qin Y
,
Li W
,
Xu N
,
Liu B
,
Zhang Y
,
Meng L
,
Zhu H
,
Du X
, et al.
Correction: Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial.
J Hematol Oncol. 2023;16(1):13.
PubMed
Google Scholar